About Us

Luye Pharma Group (02186.HK), a member of Luye Life Sciences Group, is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications.

On The Road

Luye Pharma Signs Two Agreements in Latin America, Global Business System for Seroquel Continues to Grow Rapidly

News

Luye Pharma Group recently signed two agreements with partners in Latin America, boosting further development of the central nervous system (CNS) drugs Seroquel® (quetiapine fumarate, immediate release, IR) and Seroquel XR® (extended release formulation) in the local markets

September 11,2020

Luye Pharma’s New Alzheimer’s Drug LY03013 Starts Clinical Trials in China

Luye Pharma Group announced today that the company has received the approval from the Center for Drug Evaluation of China to begin clinical trials for the new drug product Rivastigmine Multi-Day Transdermal Patch (Rivastigmine MD, LY03013). The product was developed for the treatment of Alzheimer's disease by Luye Pharma AG, the company’s German subsidiary, on its proprietary transdermal patch platform. Marketing Authorization applications for Rivastigmine MD have been formally accepted and are under review by the relevant authorities in seven European countries: Germany, the United Kingdom, Spain, Italy, Portugal, Luxembourg and Greece.

September 01,2020

Read More

Investors

Employee Stories

Upholding the philosophy of “Employee Development”,
Luye Pharma regards employees as the most valuable resources of the company